Business & Regulation

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

ADCs have shown their promise, but the next step is realizing their potential.

Lore Gruenbaum discusses The Leukemia & Lymphoma Society, advances in blood cancers, and the role of nonprofits.

FDA to phase out mandatory animal testing with human-relevant methods for drug development

Donald Trump threatens “major tariff” on pharmaceuticals.

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.